aTyr Pharma shareholders will vote on October 16 to authorize the board to execute a Reverse Stock Split ranging from 1-for-10 to 1-for-50. The proposal matters because the company expects the action could help regain and maintain Nasdaq’s $1.00 minimum bid-price compliance, though it cannot assure that result.

Key Highlights

  • Federated Hermes beneficially owned 8,509,678 aTyr Pharma shares, representing 8.68%, as of August 27.
  • The board may choose the reverse-split ratio after approval, using a range from 1-for-10 through 1-for-50.
  • The company says the post-split stock price may not remain above Nasdaq’s $1.00 minimum bid requirement.

ATyr Pharma (NASDAQ: ATYR) is asking shareholders to approve a reverse stock split ranging from 1-for-10 to 1-for-50 at a special meeting on October 16, 2026. The Board of Directors would decide whether to implement the split and select the final ratio if shareholders approve the proposal. The board recommends voting FOR the measure. A second proposal covers any other Business properly brought before the meeting.

October 16 Reverse-Split Vote

Shareholders recorded as of September 4, 2026 will be entitled to notice of and vote at the special meeting. The meeting is scheduled for 9:00 a.m. Pacific Time at aTyr Pharma’s headquarters at 10,240 Sorrento Valley Road, San Diego, California. Proposal 1 concerns alternate amendments to the company’s restated certificate of incorporation. Approval would give the board authority, at its sole discretion, to carry out a reverse stock split of common stock at any ratio from 1-for-10 to 1-for-50, inclusive. The authorization would not require the board to complete a reverse split. The board could also determine the ratio after Shareholder approval. Proposal 2 permits consideration of other business that may properly come before the meeting.

Board Holds Ratio Authority

The company says the board may consider historical and prevailing trading prices and trading volumes when deciding whether to implement the reverse split and which ratio to use. It may also assess the expected effect on the trading market over the short and long term. Nasdaq listing compliance is another Factor identified by the company. Administrative cost is also listed among the considerations. The board may evaluate which ratio would create the least administrative cost, along with general market and economic conditions. The board may further consider whether and when it wants additional authorized but unissued common stock available for business or financial purposes and for future Equity awards.

Nasdaq Price Risk Remains

ATyr Pharma expects a reverse split could increase the Market Price of its common stock and help it regain compliance with Nasdaq’s $1.00 minimum bid-price requirement. The company says the market-price effect cannot be predicted with certainty. The price also may not exceed or remain above the $1.00 minimum bid level for a sustained period. The company says the action may not produce a share price that attracts Brokers and investors who avoid lower-priced stocks. It also says some investors may view a reverse split negatively.

Ownership Before the Meeting

As of August 27, 2026, aTyr Pharma had 98,087,425 shares of common stock issued and outstanding. Federated Hermes beneficially owned 8,509,678 shares, equal to 8.68%. Sanjay S. Shukla beneficially owned 2,755,748 shares, or 2.74%, including 153,553 shares owned and 2,602,195 shares acquirable within 60 days. Jill M. Broadfoot held 39,796 shares and had 899,584 shares acquirable within 60 days, for 939,380 beneficially owned shares. Nancy E. Denyes held 35,624 shares and had 897,574 shares acquirable within 60 days, for 933,198 beneficially owned shares. Timothy P. Coughlin held 56,000 shares and had 95,425 shares acquirable within 60 days, for 151,425 beneficially owned shares. The group of current directors and executive officers held 306,723 shares and had 4,876,456 shares acquirable within 60 days.